Anxiety disorders, a widespread mental health concern, encompass a range of conditions, each with specific characteristics and treatment protocols. However, the realm of “unspecified anxiety disorder” remains a grey area, often challenging healthcare professionals due to its lack of clear-cut guidelines. A recent study aimed to fill this gap by developing a consensus among experts …
Fetzima (Levomilnacipran), is a serotonin-norepinephrine reuptake inhibitor (SNRI) that was approved by the United States FDA in 2013 for the treatment of major depressive disorder. It was engineered to be a spinoff (or some might suggest an upgraded or slightly modified version) of the drug Savella (Milnacipran). Comparatively, Fetzima solely contains the levorotatory enantiomer of …
Omeprazole, manufactured the trade names Prilosec and Losec, is a proton-pump inhibitor prescribed for the management of medical conditions such as: gastroesophageal reflux disease (GERD); peptic ulcer disease; Zollinger-Ellison syndrome; and forms of esophagitis (erosive and eosinophilic). In some cases, omeprazole is also utilized as a prophylactic to prevent upper gastrointestinal bleeding in at-risk populations. …
Rexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in some cases, as an add-on (adjunct) treatment for refractory major depressive disorder. Throughout the central nervous system, the medication exerts neurophysiologic effects across dopaminergic, serotonergic, noradrenergic, and histaminergic targets. Receptor sites most targeted …
Vraylar (Cariprazine) is an atypical antipsychotic that is most frequently prescribed as a pharmacological intervention for schizophrenia and bipolar disorder. The medication functions predominantly as a: D3 and D2 receptor partial agonist, 5-HT2B receptor antagonist, and 5-HT1A partial agonist. To a less significant extent, Vraylar interacts with H1 receptors and 5-HT2A receptors as an antagonist. …
Tianeptine, also referred to under the brand names “Stablon” and “Coaxil,” is an antidepressant originally discovered and patented in the 1960s by the French Society of Medical Research. The drug is primarily utilized for the treatment of major depressive disorder in France and European countries. In some cases, tianeptine is also utilized for the management …
Bunavail is a bucally-formatted medication comprised of buprenorphine and naloxone that was approved by the FDA in 2017 for the treatment of opioid dependence. The buprenorphine component of Bunavail functions as a partial mu-opioid receptor agonist whereby it stimulates mu-opioid receptors in the brain to prevent opioid cravings and/or attenuate harsh withdrawal symptoms upon cessation …